Chronic cholecystitis medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Cholecystitis}}
{{Cholecystitis}}
==Overview==
==Medical Therapy==
==Medical Therapy==



Revision as of 21:39, 11 August 2015

Chronic cholecystitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cholecystitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Chronic cholecystitis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Chronic cholecystitis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Chronic cholecystitis medical therapy

CDC on Chronic cholecystitis medical therapy

Chronic cholecystitis medical therapy in the news

Blogs on Chronic cholecystitis medical therapy

Directions to Hospitals Treating Cholecystitis

Risk calculators and risk factors for Chronic cholecystitis medical therapy

Overview

Medical Therapy

  • 1. Community-acquired acute cholecystitis of mild-to-moderate severity [1]
  • Preferred regimen (1): Cefazolin 1–2 g IV q8h
  • Preferred regimen (2): Cefuroxime 1.5 g IV q8h
  • Preferred regimen (3): Ceftriaxone 1–2 g IV q12–24 h
  • 2. Community-acquired acute cholecystitis of severe physiologic disturbance, advanced age, or immunocompromised state [1]
  • 3. Acute cholangitis following bilio-enteric anastamosis of any severity [1]
  • 4. Health care-associated biliary infection of any severity [1]
  • Note(1): Antimicrobial therapy of established infection should be limited to 4–7 days, unless it is difficult to achieve adequate source control. Longer durations of therapy have not been associated with improved outcome.
  • Note(2): Patients undergoing cholecystectomy for acute cholecystitis should have antimicrobial therapy discontinued within 24 h unless there is evidence of infection outside the wall of the gallbladder.

References

  1. 1.0 1.1 1.2 1.3 Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ; et al. (2010). "Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America". Clin Infect Dis. 50 (2): 133–64. doi:10.1086/649554. PMID 20034345.


Template:WikiDoc Sources